UPL, Godrej & more: Top stocks to buy on November 10 – Check list
Citigroup has a buy rating on Apollo Hospitals with the target price at Rs 9,330.
Analysts said the company’s Q2FY26 numbers were in line with expectations with HealthCo delivering healthy margin expansion.
They pointed out that its hospital business saw slight year-on-year (YoY) margin contraction, due to a high base.Goldman Sachs maintained its buy rating on Crompton Greaves Consumer Electricals with the target price slightly lowered at Rs 330 from Rs 340 earlier.
Analysts said that during Q2FY26, the company’s revenue was up 1% YOY, EBITDA was 18% below estimates while margin was down to 8.3%.
Its lighting and butterfly segments improved, the electrical consumer durables (ECD) segment reported weak numbers due to lower table-pedestal-wall-mounted fans and appliances sales, and higher input costs.
During the quarter the company also won two rooftop solar orders worth Rs 500 crore, marking entry into a new growth area, which is expected to be margin-neutral.
Despite a soft quarter, risk-reward remains favourable.
The stock is seen as one of the cheapest consumer durable plays among the stocks Goldman Sacks covers.Elara maintained its reduce rating on Alkyl Amines with the target price cut to Rs 1,825 from Rs 1,872 earlier.
Analysts said the company’s volume growth was marginal in the April-Sept half year (HIFY26).
The company also gave a subdued guidance amid weak demand, US sanctions, and Chinese competition.
Currently the global methylamines market is in an oversupply zone, particularly in the EU while the domestic segment faces overcapacity. The company’s new product project to be commissioned in Q1FY27, with expected asset turnover of 1.5x.
Also, anti-dumping duty on acetonitrile has yet to show full impact.Jefferies has a buy rating on Godrej Properties with the target price at Rs 3,000.
Analysts said the company’s pre-sales during Q2FY26 was strong and it is expected to beat its guidance.
They also expect the company’s cash flow to improve in H2FY26.
They also raised its sales estimates and said the stock is attractively valued.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own.
These opinions do not represent the views of The Times of India)
